Skip to main content
. Author manuscript; available in PMC: 2024 Oct 18.
Published in final edited form as: J Med Chem. 2024 Jul 25;67(15):13033–13055. doi: 10.1021/acs.jmedchem.4c01005

Figure 4.

Figure 4

HepG2 cells cytotoxicity profile for compounds 1a and 4c. Tipifarnib, a FDA approved non-peptidomimetic quinolinone used in cancer therapy was used as a positive control for the CC50 calculations (concentration that reduced cell viability by 50%). Measurements were performed in triplicate. Error bars, S.D.